CurrentBlue Cross Blue Shield - IowaPolicy N/A

New-to-market drug list (coverage criteria)

Identifies FDA-approved prescription drugs newly introduced to market that are currently considered non-covered pending review by the Wellmark Pharmacy & Therapeutics (P&T) Committee; applies to Blue Cross Blue Shield - Iowa benefit administration.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyNew-to-market drug list (coverage criteria)

Policy CodePolicy N/A

Change TypeAdministrative list (no material changes)

Effective DateN/A

Next Review DateN/A

Key ActionExpect listed new-to-market drugs to be non-covered pending P&T Committee review; plan for potential denials until coverage is determined.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

14drugs listed awaiting P&T review

mostdefault coverage stance

Wellmark P&Tresponsible review body

Coverage Criteria

The drugs listed on this new-to-market list are considered non-covered for most benefits during the Pharmacy & Therapeutics (P&T) evaluation period. Coverage determinations for these products will be made following review by the Wellmark P&T Committee.

Provider Actions & Operational Notes

Prior Authorization

Prior authorization expectation — New-to-market drugs

Drugs on this new-to-market list are considered non-covered pending evaluation by the Wellmark Pharmacy & Therapeutics (P&T) Committee; providers should expect authorization/coverage denial until review completes.

New, FDA-approved prescription drugs listed are considered non-covered for most benefits during the evaluation period and may be denied until P&T review.
Providers may submit clinical information to support coverage consideration during the P&T review process.

Step Therapy

Step therapy — Not specified

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyNew-to-market drug list (coverage criteria)

Policy CodePolicy N/A

Change TypeAdministrative list (no material changes)

Effective DateN/A

Next Review DateN/A

Key ActionExpect listed new-to-market drugs to be non-covered pending P&T Committee review; plan for potential denials until coverage is determined.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

No step therapy requirements are specified for the products on this list in this document.

Documentation Required

Documentation

No document-specific prior authorization forms or documentation requirements are specified in this list. However, providers should retain and be prepared to submit clinical records, FDA labeling, and any supporting literature if requesting coverage or appealing a denial during the evaluation period.

Retain clinical records supporting medical necessity (diagnosis, prior treatments, treatment rationale).
Be prepared to provide FDA labeling, peer-reviewed literature, and any specialty pharmacy documentation if requested.

Denial Risk

Non-coverage during evaluation

New, FDA-approved prescription drugs listed are considered non-covered for most benefits during the evaluation period and therefore may be denied until P&T review.

Generics are in italics; brand names are CAPITALIZED on the list.
Example listed products awaiting review: QIVIGY®, AQVESME™, AVLAYAH™, EXDENSUR™, FOUNDAYO™, ICOTYDE™, IDVYNSO™, LEROCHOL®, LOARGYS®, LIFYORLI™, MYQORZO™, ORLADEYO®, SAPHNELO™ Pen, YUVIWEL®, ZYCUBO®.

Background

This is an administrative notification that FDA-approved prescription drugs newly introduced to the market undergo an evaluation period by the payer’s Pharmacy & Therapeutics (P&T) Committee. While under review, these products are generally treated as non-covered for most benefits pending the Committee’s coverage decision.

Definitions

New-to-market drugs — definition

DefinitionFDA‑approved prescription drugs that are newly introduced to the market and are awaiting review by the Wellmark Pharmacy & Therapeutics (P&T) Committee to determine coverage.

Coverage stance during evaluationConsidered non‑covered for most benefits while under P&T Committee review.

Responsible review bodyWellmark Pharmacy & Therapeutics (P&T) Committee.

Typical provider expectationCoverage decisions (including any prior authorization requirements) will be determined after P&T review completes.

Example drugs on listQIVIGY; AQVESME; AVLAYAH; EXDENSUR; FOUNDAYO; ICOTYDE; IDVYNSO; LEROCHOL; LOARGYS; LIFYORLI; MYQORZO; ORLADEYO; SAPHNELO Pen; YUVIWEL; ZYCUBO.